Abstract: There is provided a labeling precursor compound represented by the general formula (2): wherein S represents a substrate, L represents a straight alkyl group having 1 to 6 carbon atoms which may contain an ether group, R1 and R2 each independently represent a straight or branched alkyl group having 1 to 30 carbon atoms, or a substituted or unsubstituted monocyclic or condensed polycyclic aryl group, R3 each independently represent an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms, and p represents an integer of 0 to 4.

Abstract: Provided is a method for producing flutemetamol including the steps of: reacting a precursor compound represented by a predetermined general formula with a radioactive fluoride to obtain a 18F labeling compound represented by a predetermined general formula; allowing a strong base to act on the reaction mixture of the above step containing the precursor compound and the 18F labeling compound; after the above step, purifying the 18F labeling compound using a reverse phase solid phase extraction cartridge; and removing a protective group to obtain [18F]flutemetamol.

Abstract: A simple method for producing a clinically applicable radiopharmaceutical composition containing 1-(2,2-dihydroxymethyl-3-[18F]fluoropropyl)-2-nitroimidazole ([18F]DiFA) or a salt thereof as an active ingredient, is provided which includes a synthesis step of obtaining a crude product of [18F]DiFA from a labeling precursor compound for [18F]DiFA; and a purification step of purifying the crude product, in which the purification step includes purifying [18F]DiFA using two or more different types of reverse phase solid phase extraction cartridges.

Abstract: One embodiment of the present invention addresses the problem of reducing the influence of physiological accumulation in monitoring nuclear medical image data. To solve this problem, the embodiment includes: extracting a bone area from CT image data having been positioned with nuclear medical image data; in the nuclear medical image data, displaying the data of an area overlapping the bone area extracted above; and, in the nuclear medical image data, not displaying the data of an area not overlapping the bone area extracted above.

Abstract: The present invention addresses the problem of providing a technique for detecting a lesion of a heart disease in a non-invasive manner. The present invention provides a non-invasive diagnostic imaging agent for a heart disease, which contains a radioactively labeled compound capable of binding to an aldosterone synthase or a salt thereof as an active ingredient.

Abstract: [Problem to be Solved] To improve stability of automatic normalization of a bone scintigraphy image. [Solution] A preferred embodiment includes: creating a pixel value histogram of image data representing a bone scintigraphy image; setting a plurality of thresholds related to pixel values based on the pixel value histogram; calculating respective average pixel values for the set thresholds; arranging the calculated average pixel values in order from the largest value; and determining a reference value for normalizing the image data based on at least part of a set of the average pixel values arranged in the order. The determining the reference value includes: determining one straight line that approximates a region of small average pixel values out of the set of the average pixel values arranged in the order; and calculating the reference value based on the straight line.

Abstract: Provided is a medicament comprising the compound represented by the following general formula (1) or a salt thereof: In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined. Methods for producing various radioactive compounds are also provided.

Abstract: Provided is a medicament comprising the compound represented by the following general formula (1) or a salt thereof: In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined. Methods for producing various radioactive compounds are also provided.

Abstract: Provided is a highly reliable technique for the evaluation of ischemic conditions. A preferred embodiment is a nuclear medicine measurement protocol in which the administration of a radiopharmaceutical agent and radiation measurement are performed twice at rest and under stress. In the nuclear medicine measurement protocol, radiation collection is performed without radiopharmaceutical agent administration before the second radiopharmaceutical agent administration, and the result is used to correct the nuclear medicine measurement result after the second radiopharmaceutical agent administration.

Abstract: Provided is a method for producing flutemetamol including the steps of: reacting a precursor compound represented by a predetermined general formula with a radioactive fluoride to obtain a 18F labeling compound represented by a predetermined general formula; allowing a strong base to act on the reaction mixture of the above step containing the precursor compound and the 18F labeling compound; after the above step, purifying the 18F labeling compound using a reverse phase solid phase extraction cartridge; and removing a protective group to obtain [18F]flutemetamol.

Abstract: Provided is a compound represented by general formula (1) or a salt thereof as well as a medicine containing the compound or the salt. In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined.

Abstract: The present invention relates to a radioactive halogen-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a specific general formula or a salt thereof, or a radiopharmaceutical comprising the same.

Abstract: There is provided a labeling precursor compound represented by the following general formula (2): wherein R1 represents an alkynyl group, an alkynyloxy group, an azide group, an azidoalkyl group, an arylazide group, a monocyclic or condensed polycyclic aryl group or a nitrogen-containing heterocycle; R2 and R3 each independently represent an alkyl group or a hydroxyalkyl group which hydroxy group may be protected with a protecting group, and n is an integer of 1 or 2; R6 represents an alkyl group or —CONR11R12 wherein R11 and R12 each independently represent an alkyl group or a monocyclic or condensed polycyclic aryl group; and R4, R5, R7 and R8 each independently represent a hydrogen atom, an alkyl group or an alkoxy group.

Abstract: The present invention relates to a radioactive iodine-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a definite general formula or a salt thereof, or a radiopharmaceutical comprising the same.

Abstract: In imaging analysis of a living body, a Region Of Interest (ROI) is set on the basis of the state of radiopharmaceutical accumulation. An example for setting an ROI includes: performing first transformation for anatomically standardizing, with the use of a positive template, a nuclear medicine image acquired by applying a radiopharmaceutical to a subject; performing second transformation for anatomically standardizing, with the use of a negative template, the nuclear medicine image; calculating a degree of similarity between a first anatomical standardization image acquired by the first transformation and the positive template; calculating a degree of similarity between a second anatomical standardization image acquired by the second transformation and the negative template; and applying, to an ROI template, inverse transformation of the first transformation or the second transformation, whichever has the higher of the calculated degrees of similarity, in order to set the ROI.

Abstract: Provided is a method for imaging a renal lesion comprising the steps of administrating a nitroimidazole-based compound to a living body and obtaining an image of the renal lesion by detecting radiation non-invasively from the outside of the living body wherein the renal imaging agent comprises a defined nitroimidazole-based compound or a salt thereof. The step of obtaining the image of the renal lesion can include using positron emission tomography.

Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.

Abstract: An apparatus for producing a radiolabeled compound is a production apparatus which produces a radiolabeled compound by introducing a radioisotope into a non-radioactive labeling precursor compound. The production apparatus includes a solid phase extraction unit in which a specific process which is a reaction of an intermediate compound, a purification of the intermediate compound, or a purification of the radiolabeled compound is carried out; and a cooling unit that cools the solid phase extraction unit, when the specific process is carried out.

Abstract: There is provided a diagnostic imaging agent for early bone metastasis from cancer, containing trans-1-amino-[18F]fluorocyclobutanecarboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: The present invention relates to a radioactive iodine-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a definite general formula or a salt thereof, or a radiopharmaceutical comprising the same.